Akums Drugs and Pharmaceuticals IPO Details, Financials, Valuation & Peers
Get everything you need to know about the Akums Drugs and Pharmaceuticals IPO. Explore Akums Drugs and Pharmaceuticals IPO details, including IPO dates, financial statements, valuation, peer comparison, and more.
Overview
Akums Drugs and Pharmaceuticals Limited is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) established in 2004. As a leading CDMO in India, Akums offers a comprehensive range of pharmaceutical services, including end-to-end product development, manufacturing, formulation research and development, and regulatory filing. The company is involved in producing a variety of dosage forms such as tablets, capsules, liquid orals, and injectables. With a substantial market share and a strong presence in both domestic and international markets, Akums caters to major pharmaceutical companies and maintains high standards through its accredited manufacturing units. The company also engages in the marketing of its own branded formulations and has expanded its capabilities through strategic acquisitions.
Key Points:
- Comprehensive Services:
- Offers end-to-end solutions including formulation R&D, regulatory dossier preparation, and testing services.
- Produces a wide range of dosage forms such as tablets, capsules, liquid orals, vials, and injectables.
- Market Leadership:
- Largest India-focused CDMO by revenue, production capacity, and clients served.
- Held a 30.2% market share of the Indian domestic CDMO market in FY 2024.
- Manufacturing Capacity:
- Operates 10 manufacturing units with a cumulative annual capacity of 49.23 billion units as of March 31, 2024.
- New injectable facility expected to be operational by FY 2025.
- Innovation and R&D:
- Operates four dedicated R&D units with a team of 406 scientists.
- Developed 222 innovative formulations and secured approval for 927 formulations and five patents as of March 31, 2024.
- Strategic Acquisitions:
- Acquired Akums Lifesciences Limited in 2021, adding new manufacturing units and R&D capabilities.
- Expanded into API manufacturing with an installed capacity of 737.38 MT.
- Domestic and International Marketing:
- Operates through subsidiaries Akumentis and Unosource for domestic and international markets.
- Focuses on various therapeutic areas including gynaecology, cardiology, anti-infectives, and more.
Objects of the Issue
- Repayment/ prepayment of indebtedness of the Company
- Repayment/ prepayment of indebtedness of the Subsidiaries namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited;
- Funding incremental working capital requirements of the Company
- Pursuing inorganic growth initiatives through acquisitions
- General corporate purposes.
IPO Details
Discover essential information crucial for understanding an IPO, including the Price Band, Fresh Issue, Offer For Sale, Total IPO Size and more. Explore these key details to gain insight into the company's public offering.
| Fields | Details |
|---|---|
| IPO Dates | 30 Jul - 01 Aug 2024 |
| IPO Price Band | ₹ 646 - 679 per share |
| Fresh Issue | ₹ 680 crore |
| Offer For Sale | 17,330,435 shares (₹ 1,176.74 crore) |
| Total IPO Size | Approx ₹ 1,856.74 crore |
| Face Value | ₹ 2 |
| Listing On | BSE, NSE |
IPO Timeline
Explore important dates like IPO opening, closing, listing and others, outlining the journey of the Public Offering. This will help you grasp the entire IPO journey effortlessly.
| Event | Date |
|---|---|
| IPO Opening Date | 30 Jul 2024 |
| IPO Closing Date | 01 Aug 2024 |
| Basis Of Allotment | 02 Aug 2024 |
| Refunds | 05 Aug 2024 |
| Demat Transfer | 05 Aug 2024 |
| IPO Listing Date | 06 Aug 2024 |
Financial Statements
Explore a comprehensive financial data table showcasing key metrics including revenue, expenses, net income, and others. Gain valuable insights about the company's financial performance at a glance, facilitating informed decision-making and strategic planning for subscribing to the IPO.
| Period Ended | 31st March 2021 | 31st March 2022 | 31st March 2023 | 31st March 2024 |
|---|---|---|---|---|
| Total Income | 2,743.79 | 3,694.52 | 3,700.93 | 4,212.21 |
| Total Expenses | 2,561.87 | 3,874.95 | 3,475.93 | 4231.45 |
| Net Profit/Loss | 123.44 | -250.87 | 97.82 | 0.79 |
| NPM (*) | 4.50 | -6.79 | 2.64 | 0.02 |
| Total Assets | 2,166.87 | 3,069.05 | 3,266.53 | 3,516.37 |
| Total Liabilities | 1,279.74 | 2,443.88 | 2,543.15 | 2,795.88 |
* NPM represents the net profit margin, calculated as a percentage. All other figures are presented in crore (₹cr)
Valuation
Uncover significant valuation metrics such as EPS (Earnings Per Share), ROE (Return on Equity), ROCE (Return on Capital Employed), D/E Ratio (Debt-to-Equity Ratio), Current Ratio, and EBITDA Margin. These key indicators offer insights into the company's financial standing and performance, aiding in informed investment decisions.
| Period Ended | 31st March 2021 | 31st March 2022 | 31st March 2023 | 31st March 2024 |
|---|---|---|---|---|
| EPS | 8.58 | -17.65 | 6.63 | -0.28 |
| ROE (%) | 13.91 | -40.13 | 13.52 | 0.11 |
| ROCE (%) | 21.06 | -18.89 | 24.60 | 3.37 |
| D/E Ratio | 0.11 | 0.58 | 0.75 | 0.69 |
| Current Ratio | 2.00 | 1.46 | 1.48 | 1.60 |
| EBITDA MARGIN (%) | 9.42 | -1.87 | 10.38 | 3.73 |
* Compiled from DRHP/RHP for valuation purposes.
Peer Comparison
Compare key financial metrics with industry peers to gain valuable insights into the company's performance compared to its competitors.
| Name | Revenue | P/E | EPS | RoNW | NAV |
|---|---|---|---|---|---|
| Akums Drugs and Pharmaceuticals | 4,178.18 | -2,425 | -0.28 | -0.57 | 49.59 |
| Divi's Laboratories | 7,845.0 | 74.99 | 60.27 | 11.79 | 511.21 |
| Suven Pharma | 1,051.35 | 69.54 | 11.80 | 14.64 | 80.56 |
| Gland Pharma | 5,664.72 | 42.45 | 46.89 | 8.85 | 529.65 |
| Torrent Pharma | 10,728.0 | 60.20 | 48.94 | 24.15 | 202.57 |
| Alkem Laboratories | 12,667.58 | 34.18 | 150.19 | 17.41 | 862.46 |
| Eris Lifesciences | 2,009.14 | 34.95 | 28.79 | 15.16 | 190.12 |
| JB Chemicals | 3,484.18 | 51.38 | 34.85 | 18.90 | 188.37 |
| Mankind Pharma | 10,334.77 | 44.65 | 47.68 | 20.43 | 233.73 |
| Innova Captab | 1,081.31 | 29.91 | 18.66 | 11.35 | 145.20 |
* Revenue in (₹cr), RoNW in (%), EPS, NAV in (₹). P/E ratio is based on the highest price from the IPO price band.
Subscription Data from NSE and BSE
| Investor Type | Subscribed |
|---|---|
| Qualified Institutional Buyer (QIB) | 90.09 |
| Non-Institutional Investor (NII/HNI) | 42.1 |
| Retail Individual Investor (RII) | 20.8 |
| Total | 63.44 |
* All figures represent multiples of the subscription. Check subscriptions for other ongoing issues here.
IPO Registrar
MUFG Intime India Private Limited (Formerly known as Link Intime India Private Limited)
Phone: + 91 810 811 4949
Email: ipo.helpdesk@linkintime.co.in
Website: https://linkintime.co.in/
Company Promoters
- SANJEEV JAIN
- SANDEEP JAIN
- AKUMS MASTER TRUST
Lead Managers
- ICICI Securities Limited
- Axis Capital Limited
- Citigroup Global Markets India Private Limited
- Ambit Private Limited
Company Address
Akums Drugs and Pharmaceuticals Limited
304, Mohan Place, LSC Saraswati Vihar, Delhi 110 034, India
Phone: + 91 11 6904 1000
Email: cs@akums.net
Website: www.akums.in
FAQs
- What is the issue size of the Akums Drugs and Pharmaceuticals IPO?The Akums Drugs and Pharmaceuticals IPO has an issue size of Approx ₹ 1,856.74 crore. This includes a fresh issue of ₹ 680 crore and an offer for sale (OFS) of 17,330,435 shares (₹ 1,176.74 crore).
- What is the price band of the Akums Drugs and Pharmaceuticals IPO?The price band for the Akums Drugs and Pharmaceuticals IPO is ₹ 646 - 679 per share.
- What are the bidding dates for the Akums Drugs and Pharmaceuticals IPO?The Akums Drugs and Pharmaceuticals IPO will open for bidding on 30 Jul 2024 and close on 01 Aug 2024.
- What is the allotment date for the Akums Drugs and Pharmaceuticals IPO?The allotment date for the Akums Drugs and Pharmaceuticals IPO is 02 Aug 2024.
- What is the listing date for the Akums Drugs and Pharmaceuticals IPO?The listing date for the Akums Drugs and Pharmaceuticals IPO is 06 Aug 2024.
- What is the Akums Drugs and Pharmaceuticals IPO grey market premium?The grey market premium (GMP) for the Akums Drugs and Pharmaceuticals IPO is currently at ₹43, with an expected listing gain of approximately 6.33%. Remember, the grey market premium is not an official indicator, but it reflects market perception and demand for the IPO shares.